MA42037B1 - Protéines de fusion - Google Patents

Protéines de fusion

Info

Publication number
MA42037B1
MA42037B1 MA42037A MA42037A MA42037B1 MA 42037 B1 MA42037 B1 MA 42037B1 MA 42037 A MA42037 A MA 42037A MA 42037 A MA42037 A MA 42037A MA 42037 B1 MA42037 B1 MA 42037B1
Authority
MA
Morocco
Prior art keywords
fusion proteins
present
extended
diabetes
time
Prior art date
Application number
MA42037A
Other languages
English (en)
French (fr)
Inventor
Craig Duane Dickinson
David Bruce Baldwin
John Michael Beals
Jonathan Wesley Day
Andrew Ihor Korytko
Gregory Alan Lazar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55953435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42037(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA42037B1 publication Critical patent/MA42037B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
MA42037A 2015-05-07 2016-04-28 Protéines de fusion MA42037B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158079P 2015-05-07 2015-05-07
EP16721605.0A EP3292141B1 (en) 2015-05-07 2016-04-28 Fusion proteins
PCT/US2016/029807 WO2016178905A1 (en) 2015-05-07 2016-04-28 Fusion proteins

Publications (1)

Publication Number Publication Date
MA42037B1 true MA42037B1 (fr) 2020-03-31

Family

ID=55953435

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42037A MA42037B1 (fr) 2015-05-07 2016-04-28 Protéines de fusion

Country Status (40)

Country Link
US (5) US9855318B2 (enExample)
EP (1) EP3292141B1 (enExample)
JP (1) JP6591562B2 (enExample)
KR (1) KR102059736B1 (enExample)
CN (1) CN107531806B (enExample)
AR (1) AR105616A1 (enExample)
AU (1) AU2016257659B2 (enExample)
CA (1) CA2981102A1 (enExample)
CL (1) CL2017002761A1 (enExample)
CO (1) CO2017011301A2 (enExample)
CR (1) CR20170469A (enExample)
CY (1) CY1122929T1 (enExample)
DK (1) DK3292141T3 (enExample)
DO (1) DOP2017000258A (enExample)
EA (1) EA039770B1 (enExample)
EC (1) ECSP17073650A (enExample)
ES (1) ES2799099T3 (enExample)
HR (1) HRP20200503T1 (enExample)
IL (1) IL254965B (enExample)
JO (1) JO3658B1 (enExample)
LT (1) LT3292141T (enExample)
MA (1) MA42037B1 (enExample)
MD (1) MD3292141T2 (enExample)
ME (1) ME03709B (enExample)
MX (1) MX388594B (enExample)
MY (1) MY183025A (enExample)
NZ (1) NZ736470A (enExample)
PE (1) PE20180507A1 (enExample)
PH (1) PH12017502025A1 (enExample)
PL (1) PL3292141T3 (enExample)
PT (1) PT3292141T (enExample)
RS (1) RS60044B1 (enExample)
SG (1) SG11201708194WA (enExample)
SI (1) SI3292141T1 (enExample)
SV (1) SV2017005548A (enExample)
TN (1) TN2018000059A1 (enExample)
TW (1) TWI656132B (enExample)
UA (1) UA122146C2 (enExample)
WO (1) WO2016178905A1 (enExample)
ZA (1) ZA201706334B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
ES2839208T3 (es) 2016-07-27 2021-07-05 Hewlett Packard Development Co Interfaz horizontal para cartucho de suministro de fluido que tiene sensor digital de nivel de fluido
BR112019011860A2 (pt) * 2016-12-09 2019-11-12 Akston Biosciences Corp proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
WO2018185131A2 (en) 2017-04-05 2018-10-11 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
BR112020015016A2 (pt) 2018-01-26 2020-12-29 Genentech, Inc. Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
BR112020025287A2 (pt) 2018-06-25 2021-03-09 University Of Washington Projeto de novo de miméticos de interleucina potentes e seletivos
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
SI4186920T1 (sl) 2018-06-29 2024-05-31 Akston Biosciences Corporation Ultra dolgo delujoči inzulin-FC fuzijski proteini in postopki uporabe
JP2022502467A (ja) 2018-10-10 2022-01-11 ノヴォ ノルディスク アー/エス オリゴマー伸長インスリン−fcコンジュゲートおよびそれらの医学的使用
CN112912388A (zh) 2018-11-20 2021-06-04 华盛顿大学 分拆白介素模拟物和它们的用途
EP3937904A1 (en) * 2019-03-15 2022-01-19 Eli Lilly and Company Preserved formulations
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
CA3159486A1 (en) * 2019-12-19 2021-06-24 Thomas M. Lancaster Ultra-long acting insulin-fc fusion proteins and methods of use
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP4121449A2 (en) 2020-03-16 2023-01-25 Neoleukin Therapeutics, Inc. Interleukin-2 receptor beta (il-2rb) binding polypeptides
JP2023521706A (ja) 2020-04-07 2023-05-25 ネオロイキン セラピューティクス, インコーポレイテッド アンギオテンシン変換酵素2(ace2)のデノボタンパク質デコイ
WO2021207599A1 (en) 2020-04-10 2021-10-14 Akston Biosciences Corporation Antigen specific immunotherapy for covid-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
JP7532638B2 (ja) * 2020-07-24 2024-08-13 チアンスー ジェンサイエンス インコーポレイテッド インスリン-Fc融合タンパク質及びその応用
WO2022096704A1 (en) * 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
EP4259186A1 (en) * 2020-12-14 2023-10-18 Eli Lilly and Company Methods of treating diabetes
EP4373861A4 (en) 2021-07-23 2025-08-20 Akston Biosciences Corp INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
TWI871539B (zh) * 2021-11-15 2025-02-01 美商美國禮來大藥廠 可保存之調配物
US20250206797A1 (en) * 2022-03-16 2025-06-26 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Human insulin analogue, and fusion protein thereof and medical use thereof
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
EP4543909A1 (en) 2022-06-23 2025-04-30 Sanofi Single chain insulins and fc conjugates thereof
WO2024137820A1 (en) * 2022-12-20 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Insulin receptor antagonist
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白
WO2024229093A1 (en) 2023-05-03 2024-11-07 Eli Lilly And Company Methods and systems for managing diabetes
WO2025059010A1 (en) 2023-09-11 2025-03-20 Eli Lilly And Company Methods and systems for managing diabetes
WO2025061146A1 (zh) * 2023-09-20 2025-03-27 上海迈晋生物医药科技有限公司 一种人胰岛素类似物融合蛋白的药物组合物及其医药用途
WO2025080923A1 (en) 2023-10-13 2025-04-17 Eli Lilly And Company Insulin-fc fusion proteins
EP4669757A1 (en) 2024-03-21 2025-12-31 Akston Biosciences Corporation PD-L1 ANALOGUE FUSION PROTEINS FOR ANTIGEN-SPECIFIC IMMUNOTHERAPY AND METHODS OF USE

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2369839A1 (en) 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
ATE406384T1 (de) 2000-12-07 2008-09-15 Lilly Co Eli Glp-1 fusion proteine
BR0215029A (pt) 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
UA87458C2 (ru) 2003-06-12 2009-07-27 Елі Ліллі Енд Компані Гибридные белки-аналоги glp-1
US7448763B2 (en) 2003-10-02 2008-11-11 Carl Zeiss Smt Ag Optical subassembly and projection objective in semiconductor lithography
AU2004295023A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
US20090069216A1 (en) 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
EP1996709A2 (en) 2006-03-13 2008-12-03 Novo Nordisk A/S Acylated single chain insulin
KR101729986B1 (ko) 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
US7867491B2 (en) * 2007-05-30 2011-01-11 Genexine Co., Ltd. Immunoglobulin fusion proteins
NZ582480A (en) 2007-07-10 2011-03-31 Lilly Co Eli Glp-1-fc fusion protein formulation
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
DK2910570T3 (en) * 2008-03-18 2017-01-30 Novo Nordisk As Protease-stabilized acylated insulin analogues.
CA2722168A1 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
NZ590358A (en) 2008-07-23 2012-04-27 Hanmi Holdings Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
WO2012109429A2 (en) 2011-02-09 2012-08-16 Glaxosmithkline Llc Lyophilized formulations
CN102718870B (zh) * 2011-05-24 2014-04-30 马鞍山中美德康生物科技有限公司 一种胰岛素生物增敏剂及其应用
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
CA2886228A1 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
CN105008395B (zh) 2012-11-05 2020-12-29 卡斯西部储备大学 长效单链胰岛素类似物
BR112015018828B1 (pt) 2013-02-26 2024-01-30 Hanmi Pharm Co., Ltd Conjugado de insulina sítio-específico
US9353163B2 (en) * 2013-03-14 2016-05-31 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
SG11201605680PA (en) 2014-01-20 2016-09-29 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
KR102569743B1 (ko) 2014-10-06 2023-08-23 케이스 웨스턴 리저브 유니버시티 이상 단일 사슬 인슐린 유사체
SG10201809427SA (en) 2014-11-21 2018-11-29 Merck Sharp & Dohme Insulin receptor partial agonists
WO2016133372A2 (ko) 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
CN110134210A (zh) 2019-04-16 2019-08-16 深圳市国鑫恒宇科技有限公司 一种服务器一体机的温度控制方法、系统、装置及存储介质

Also Published As

Publication number Publication date
US20180177851A1 (en) 2018-06-28
CN107531806B (zh) 2022-06-07
UA122146C2 (uk) 2020-09-25
MX2017014284A (es) 2018-03-23
US10709766B2 (en) 2020-07-14
AU2016257659A1 (en) 2017-10-12
EP3292141B1 (en) 2020-02-12
JP2018515088A (ja) 2018-06-14
EA039770B1 (ru) 2022-03-11
TWI656132B (zh) 2019-04-11
HRP20200503T1 (hr) 2020-06-26
EA201792199A1 (ru) 2018-03-30
JP6591562B2 (ja) 2019-10-16
MD3292141T2 (ro) 2020-07-31
CA2981102A1 (en) 2016-11-10
PE20180507A1 (es) 2018-03-09
MX388594B (es) 2025-03-20
AU2016257659B2 (en) 2018-08-09
RS60044B1 (sr) 2020-04-30
ZA201706334B (en) 2020-01-29
US12059452B2 (en) 2024-08-13
CR20170469A (es) 2017-11-14
NZ736470A (en) 2019-04-26
PH12017502025B1 (en) 2018-04-02
BR112017020502A2 (pt) 2018-07-03
JO3658B1 (ar) 2020-08-27
SI3292141T1 (sl) 2020-04-30
SV2017005548A (es) 2018-04-24
HK1244019A1 (en) 2018-07-27
CY1122929T1 (el) 2021-10-29
LT3292141T (lt) 2020-03-25
DOP2017000258A (es) 2017-12-31
DK3292141T3 (da) 2020-04-20
ME03709B (me) 2021-01-20
CL2017002761A1 (es) 2018-05-18
TW201712029A (zh) 2017-04-01
AR105616A1 (es) 2017-10-25
US20160324932A1 (en) 2016-11-10
US9855318B2 (en) 2018-01-02
WO2016178905A1 (en) 2016-11-10
IL254965B (en) 2021-03-25
IL254965A0 (en) 2017-12-31
US20200390865A1 (en) 2020-12-17
CO2017011301A2 (es) 2018-03-20
PL3292141T3 (pl) 2020-06-29
KR20170134614A (ko) 2017-12-06
ES2799099T3 (es) 2020-12-14
SG11201708194WA (en) 2017-11-29
PT3292141T (pt) 2020-04-22
EP3292141A1 (en) 2018-03-14
PH12017502025A1 (en) 2018-04-02
US20250032588A1 (en) 2025-01-30
KR102059736B1 (ko) 2019-12-26
US20220211818A1 (en) 2022-07-07
US11253574B2 (en) 2022-02-22
MY183025A (en) 2021-02-07
ECSP17073650A (es) 2018-02-28
CN107531806A (zh) 2018-01-02
TN2018000059A1 (en) 2019-07-08

Similar Documents

Publication Publication Date Title
MA42037B1 (fr) Protéines de fusion
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
CL2018001695A1 (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
MA40882A (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
RU2019121902A (ru) Поливалентные модуляторы регуляторных t-клеток
SA517380842B1 (ar) بروتينات دمج لمستقبل إنترليوكين-2/إنترليوكين-2 ألفا وطرق الاستخدام
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
TW201613958A (en) MIC-1 fusion proteins and uses thereof
BR112020005841A8 (pt) Peptídeo coagonista do receptor de gcg/glp-1, composição, método para tratar um paciente de uma doença ou distúrbio metabólico, e, uso de um ou mais peptídeos coagonistas.
PH12018502451A1 (en) Brain delivery protein
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
FR3038517B1 (fr) Utilisation de fragments fc modifies en immunotherapie
CY1125448T1 (el) Μεθοδοι για την ενισχυμενη αφαιρεση προσμειξεων κατα τη διαρκεια χρωματογραφιας πρωτεϊνης α
EA201991511A1 (ru) Кристаллическая структура гремлин-1 и ингибирующее антитело
IL276616A (en) Dosage for treatment with IL-22 Fc fusion proteins
EA202090084A1 (ru) Новый терапевтический ферментный слитый белок и его применение
MX2024011129A (es) Analogo de insulina humana, proteina de fusion de este y su uso medico
SG11201901435UA (en) Monoclonal antibody against melk and utilization thereof
MA38497B1 (fr) Polypeptides d'il-22 et protéines de fusion fc il-22 et leurs procédés d'utilisation
MA47671A (fr) Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf
EA201992512A1 (ru) Антигенсвязывающие белки, связывающие trem2, и пути их применения
IT201800001663A1 (it) “uso di un peptide derivato dalla proteina umana ntimp3 nella terapia della nefropatia diabetica”